Opinion|Videos|November 20, 2024
Brief Overview of MAIA, IMROZ, BENEFIT, and CEPHEUS Clinical Trials
Elizabeth O’Donnell, MD, provides a brief overview of key findings from the MAIA, IMROZ, BENEFIT, and CEPHEUS trials, highlighting significant developments in the treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
Advertisement
Episodes in this series
- Please provide a brief overview of key findings from the below trials, such as MAIA, IMROZ, BENEFIT, and CEPHEUS.
Advertisement
Related to this article
Rocbrutinib elicited an overall response rate of 63.9% in covalent BTK inhibitor–pretreated relapsed/refractory mantle cell lymphoma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
GE HealthCare and Mayo Clinic announced a novel theranostics study to explore a personalized approach to radioligand therapy for advanced prostate cancer.
The FDA has approved pegfilgrastim-pccg, a pegfilgrastim biosimilar, to decrease the incidence of infection in non-myeloid malignancies.
The FDA has approved pembrolizumab plus enfortumab vedotin in MIBC.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Revisit Every OncLive On Air Episode From June 2026
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5